Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 384-390

  Kawakami, Kyojiro ^a   Fujita, Yasunori ^a   Kato, Taku ^b   Mizutani, Kosuke ^b   Kameyama, Koji ^b   Tsumoto, Hiroki ^a   Miura, Yuri ^a   Deguchi, Takashi ^b   Ito, Masafumi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Castration resistant prostate cancer; Exosomes; Integrin 4; Taxane resistance; Vinculin

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BETA4 INTEGRIN; CD9 ANTIGEN; SMALL INTERFERING RNA; VINCULIN; ITGB4 PROTEIN, HUMAN; TAXOID; TUMOR MARKER; VCL PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CENTRIFUGATION; CONTROLLED STUDY; EXOSOME; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; UPREGULATION; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE PROGRESSION; EXOSOMES; HUMANS; INTEGRIN BETA4; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOMICS; TAXOIDS; UP-REGULATION; VINCULIN;

EID: 84931087511     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3011     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014
2. Kirby M, Hirst C and Crawford ED: Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 65: 1180-1192, 2011.
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26: 242-245, 2008.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A., Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al.; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004
5. Blagosklonny MV: NCI's provocative questions on cancer: Some answers to ignite discussion. Oncotarget 2: 1352-1367, 2011.
6. Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle 4 1693-1698, 2005
7. Kim JJ, Yin B, Christudass C.S., Terada N., Rajagopalan K, Fabry B, Lee D.Y., Shiraishi T., Getzenberg RH, Veltri RW, et al.: Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem 114 1286-1293, 2013.
8. Denzer K, Kleijmeer MJ, Heijnen H.F., Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113: 3365-3374, 2000.
9. Valadi H, Ekström K, Bossios A., Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659, 2007
10. Vlassov AV, Magdaleno S, Setterquist R and Conrad R: Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 1820: 940-948, 2012.
11. Yoshioka Y, Kosaka N, Konishi Y., Ohta H, Okamoto H, Sonoda H., Nonaka R, Yamamoto H, Ishii H, Mori M, et al.: Ultrasensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun 5: 3591, 2014
12. Kojima K, Fujita Y, Nozawa Y., Deguchi T and Ito M: MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70: 1501-1512, 2010.
13. Thery C, Amigorena S, Raposo G and Clayton A: Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3.22, 2006
14. Fujita Y, Kojima K, Ohhashi R., Hamada N, Nozawa Y, Kitamoto A., Sato A, Kondo S, Kojima T, Deguchi T, et al.: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285: 19076-19084, 2010.
15. Marfn-Aguilera M, Codony-Servat J, Kalko S.G., Fernandez PL, Bermudo R, Buxo E, Ribal M.J., Gascon P and Mellado B: Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11: 329-339, 2012.
16. Chang H, Jeung HC, Jung J.J., Kim TS, Rha SY and Chung HC: Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 125: 55-63, 2011.
17. Chien AJ and Moasser MM: Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Semin Oncol 35 (Suppl 2): S1-S14, quiz S39, 2008.
18. Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
19. Ruiz C, Holz DR, Oeggerli M, Schneider S., Gonzales IM, Kiefer JM, Zellweger T, Bachmann A., Koivisto PA, Helin HJ, et al.: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol 223: 543-552, 2011.
20. Cruz-Monserrate Z, Qiu S, Evers BM and O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol 20: 656-667, 2007
21. Geisler C, Gaisa NT, Pfister D, Fuessel S., Kristiansen G, Braunschweig T, Gostek S., Beine B, Diehl HC, Jackson AM, et al.: Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. BioMed Res Int 2015: 454256, 2015
22. Kumano M, Miyake H, Abolghait S.K., Behnsawy HM and Fujisawa M: β4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells. Oncol Lett 6: 1482-1486, 2013.
23. Yoshioka T, Otero J, Chen Y., Kim YM, Koutcher JA, Satagopan J, Reuter V., Carver B, de Stanchina E, Enomoto K, et al.: β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest 123: 682-699, 2013.
24. Gleason B, Adley B, Rao MS and Diaz LK: Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma. J Histochem Cytochem 53: 799-801, 2005
25. Lipscomb EA and Mercurio AM: Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev 24: 413-423, 2005
26. Goldmann WH, Auernheimer V, Thievessen I and Fabry B: Vinculin, cell mechanics and tumour cell invasion. Cell Biol Int 37: 397-405, 2013.
27. Srichai M and Zent R: Integrin structure and function. In: Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi A (eds). Springer, New York, pp 19-41, 2010.
28. Peng X, Nelson ES, Maiers JL and DeMali KA: New insights into vinculin function and regulation. Int Rev Cell Mol Biol 287: 191-231, 2011.
29. Banyard J, Chung I, Migliozzi M., Phan DT, Wilson AM, Zetter BR and Bielenberg DR: Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer 14 387, 2014
30. Mizutani K, Terazawa R, Kameyama K., Kato T, Horie K, Tsuchiya T., Seike K, Ehara H, Fujita Y, Kawakami K, et al.: Isolation of prostate cancer-related exosomes. Anticancer Res 34 3419-3423, 2014